Abstract
Spiramycin was tested as a chemotherapeutic plaque control agent. Sixty‐ three volunteers (29 experimental and 34 control) abstained from mechanical oral hygiene procedures for 11 weeks. The participants were divided randomly into exeperimental and control groupa and received, on a double blind basis, either 20–500 mg capsules of spiramycin or 20 capsules of placebo with directions to take 1 capsule 4 times a day for 5 days. At each examination visit intra‐oral photographs were taken, gingival and plaque indices recored, and plaque samples collected for laboratory study. In the experimental group there was a statistically significant decrease in plaque as measured by wet weight, turbidity, nitrogen, and carbogydrat parameters for at least 3 weeks. There was a significant decrease in the number of Streptococcus mutasn and S. sanguis in the plaque samples at weeks 1 and 3, but there was no detectable influence on the number of Gram‐negative organisms.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
